The nuclear transcription factor interferon regulatory factor-1 (IRF-1) is a putative tumor suppressor, but the expression and function of IRF-1 in esophageal adenocarcinoma (EA) remain unknown. We hypothesized that IRF-1 expression was reduced or lost in EA and that restoration of IRF-1 would result in the apoptosis of EA cells in vitro and the inhibition of tumor growth in vivo.
Introduction
The nuclear transcription factor interferon regulatory factor-1 (IRF-1) has been implicated as a potential tumor suppressor [1] [2] [3] [4] [5] . IRF-1 is primarily induced by interferon gamma (IFN-g), but is also induced by IFN-a, IFN-b, tumor necrosis factor-a, retinoic acid, interleukin (IL) 1, and IL-6 [1, 2, [6] [7] [8] . IFN-g leads to the activation of Janus kinase-1 (Jak-1) and Jak-2, resulting in the phosphorylation and dimerization of signal transducer and activator of transcription-1 (STAT-1). STAT-1 homodimers then translocate to the nucleus and bind to promoter IFN-g activation site elements to initiate or suppress the transcription of IFN-g -regulated genes such as IRF-1 [9] . IRF-1 subsequently binds to specific DNA sequences in several promoters (IFN-stimulated response element) to initiate the transcription of genes involved in mediating the antiviral, immunomodulatory, antiproliferative, and apoptotic effects of IFN-g signaling [2, 10, 11] .
There have been few studies demonstrating the role of IRF-1 in the pathology and treatment of gastrointestinal malignancies [5, 12] , and there have been no studies examining IRF-1 in esophageal adenocarcinoma (EA). The incidence of EA is rising more rapidly than any other tumor; currently, EA represents the most common histologic type of esophageal cancer in the United States [13 -15] . Despite advances in diagnosis and treatment, overall 5-year survival remains approximately 14% [16] . Given its potential tumor-suppressor capabilities, we evaluated IRF-1 expression and IFN-g responsiveness in three EA cell lines and examined the effects of IRF-1 overexpression on EA cell viability and tumor growth rates. Our findings demonstrate that Ad-IRF-1 infection of EA cells induces apoptosis in vitro and modestly inhibits tumor growth rates in vivo.
Materials and Methods

Cell Lines
Three human EA-derived cell lines (Seg-1, Bic-1, and Flo-1) have been previously described [17] . Seg-1 was maintained in RPMI 1640, and Bic-1 and Flo-1 were maintained in DMEM (BioWhittaker, Walkersville, MD). Media were supplemented with 10% fetal bovine serum (Atlanta Biologicals, Norcross, GA), 1% penicillin/streptomycin, and 1% L-glutamine (Invitrogen, Carlsbad, CA), and cells were propagated in a humidified environment at 37jC with 5% CO 2 .
(Madison, WI). The ERK inhibitor PD98059 (50 mM) was purchased from Calbiochem (La Jolla, CA). The c-Metspecific inhibitor PHA665752 (200 nM) [18] was provided by James Christensen (Pfizer, San Francisco, CA).
Ad-IRF-1 Construction and Infection
The Ad-IRF-1 construct has previously been described [19] . Cells were infected for 4 hours at 37jC in 5% CO 2 with either empty adenovirus (Ad-C5) or murine IRF-1 construct (Ad-IRF-1). Optimal multiplicity of infection (MOI) was determined by using Ad-eGFP and by measuring the percentage of fluorescent cells 24 and 48 hours later. Approximately 90% transduction was achieved with MOI = 100 in Seg-1 and Flo-1 and with MOI = 500 in Bic-1.
Immunoblotting
Cellular protein was extracted using lysis buffer (Cell Signaling Technology, Beverly, MA) containing 1 mM phenylmethlsulfonylfluoride (Sigma-Aldrich Corp., Atlanta, GA) and quantified using BCA protein assay kit (Pierce, Rockford, IL). Proteins were resolved using sodium dodecyl sulfate (SDS) polyacrylamide gels and subsequently transferred to nitrocellulose membranes (Bio-Rad, Hercules, CA). Membranes were blocked in 5% milk solution, incubated with primary antibody, washed, and incubated with HRP-conjugated secondary antibody. Immunoreactivity was detected using Supersignal West Pico Chemiluminescent Substrate (Pierce) and X-ray film (Eastman Kodak, Rochester, NY). Blots were stripped with 2% SDS, 100 mM b-mercaptoethanol, and 62.5 mM Tris (pH 6.8) for 20 minutes at 60jC and reprobed with anti-b-actin (SigmaAldrich Corp.).
FACScan Analysis of Apoptosis and Fas Expression
Cells were treated with a supraphysiologic dose of human IFN-g (1,000 U/ml) or infected with Ad-C5 or Ad-IRF-1, as above. For apoptosis studies, the pan-caspase inhibitor zVad (50 mM) was added to the cultures following a 4-hour infection period, and the cells were propagated for 36 hours, harvested, and stained using Annexin V (AV)-fluorescein isothiocyanate (FITC) apoptosis detection kit (BD Biosciences, San Diego, CA). For Fas cell surface expression, cells were collected and rinsed at various time points (0.5 -36 hours), as above. Cells were labeled with Apo 1-1 anti-Fas antibody and FITC-conjugated secondary antibody. Apoptosis and Fas expressions were assessed by flow cytometry using a Becton Dickinson FACSort (San Jose, CA).
In Vivo Treatment of Tumor-Bearing Mice
All animal studies were conducted in accordance with the Council on Animal Care at the University of Pittsburgh (Pittsburgh, PA). Seg-1 cells growing in log phase were resuspended in Hanks balanced salt solution, and 2.5 Â 10 6 cells were inoculated subcutaneously in the right flank of 4-to 6-week-old male nude nu/nu-nubr mice (Charles River Laboratories, Wilmington, MA). When tumors reached 30 to 35 mm 3 by perpendicular measurements, mice were randomized (n = 5 mice per group) and received intratumoral injection of 6 Â 10 8 plaque-forming units of Ad-IRF-1, Ad-C5, or PBS (in a total volume of 30 ml) every 4 days for a total of three treatments. Tumor growth was followed by serial measurements of perpendicular diameters using digital calipers. Tumor volumes were calculated according to the formula: 0.52 Â (width) 2 Â length [20] . Animals that were moribund or had tumors greater than approximately 4189 mm 3 were sacrificed.
Statistical Analysis
In vivo tumor growth rates for each treatment group were compared by estimating tumor growth curves (after regressing log-transformed tumor volumes on each day's tumor volume measurement) and by testing differences in regression coefficients. A mixed-model approach [21] , which represents individual mice as random effects and accounts for betweenand within-mouse variations, was used. A likelihood ratio test was constructed to determine the appropriate choice for model parameters. In addition to model-based results, differences in means on day 10 (as a check for adequacy of randomization) and day 26 (final day of tumor measurements) were tested with Kruskal-Wallis test [22] .
Results
IFN-g Signaling Pathway Is Intact in EA Cells
We began our study by characterizing IRF-1 expression and the IFN-g signaling pathway in three EA cell lines. By immunoblot analysis, Bic-1, Seg-1, and Flo-1 cells lack detectable IRF-1 protein in the absence of IFN-g stimulation ( Figure 1A ). All three EA cell lines express IRF-1 protein following IFN-g stimulation, with peak levels observed at 24 hours in the Seg-1 and Flo-1 cell lines and at 48 hours in the Bic-1 cell line. IRF-1 protein expression persists for 72 hours following IFN-g stimulation in all of the EA cell lines, except for Seg-1, where IRF-1 protein is undetectable at 48 hours. Obvious morphologic changes or signs of cell death were not seen, even after 72 hours of stimulation with IFN-g (data not shown). We concluded that IRF-1 protein is expressed in all three EA cell lines following IFN-g stimulation, suggesting that IRF-1 is not lost and that the IFN-g signaling pathway is intact.
Next, we overexpressed IRF-1 in the EA cell lines using an adenoviral IRF-1 vector, which was previously shown to result in the production of murine IRF-1 that is functional in human cells [19] . Figure 1B demonstrates that IRF-1 protein was expressed in all three EA cell lines 24 hours following infection with Ad-IRF-1. Infection with an empty adenovirus (Ad-C5) did not induce IRF-1 expression. Near-complete loss of cultures was observed following Ad-IRF-1 infection, suggesting treatment-induced cell death (data not shown). These results demonstrate that Ad-IRF-1 infection results in abundant IRF-1 protein expression. In contrast to IFN-g treatment, Ad-IRF-1 infection appears to induce extensive cell death in these EA cell lines.
Ad-IRF-1 Infection Induces Apoptosis in EA Cells
IRF-1 has previously been shown to induce apoptosis in other cell types [4, 19, 23, 24] . Because Ad-IRF-1 infection caused near-complete loss of cultures, we hypothesized that Ad-IRF-1 infection induced apoptosis. Thirty-six hours following infection with either Ad-C5 or Ad-IRF-1, cell viability was analyzed using flow cytometry. We observed a substantial increase in positively stained cell populations following Ad-IRF-1 infection, but not following IFN-g treatment (Figure 2A ). This effect was not observed in the cultures treated with equivalent MOI of Ad-C5, suggesting that it is due to IRF-1 expression and not nonspecific viral-induced necrosis. This effect was seen within 24 hours of infection, and the maximum percentage of nonviable cells was observed at 48 hours in all three EA cell lines. Pretreatment with the pan-caspase inhibitor zVad rescued a variable percentage of the cells from Ad-IRF-1 -induced cell death ( Figure 2 , A and B), suggesting that Ad-IRF-1 -induced cell death is, in large part, due to apoptosis. This was further supported by demonstrations of PARP cleavage and induced caspase-3 activity (data not shown). Taken together, these findings show that Ad-IRF-1 infection (but not IFN-g treatment) induces significant apoptosis in EA cells. 
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EA Cells Produce Functional IRF-1 Following IFN-g Stimulation
Several key mediators of apoptosis, including the death receptor Fas, the IRF-1 antagonist IRF-2, and the inhibitorof-apoptosis protein survivin, are known targets of IFN-g signaling [4,25 -27] . Because Ad-IRF-1 infection (but not IFN-g treatment) induced apoptosis, we hypothesized that modulation of these mediators by Ad-IRF-1 and IFN-g differed. Cell surface Fas expression increased to a similar degree following treatment with both IFN-g and Ad-IRF-1 ( Figure 3A ). This effect was evident by 12 hours and persisted for 36 hours in IFN-g -treated (but not Ad-IRF-1-infected) 
cells. Fas protein increased following all treatments, including
Ad-C5 (Figure 3B ), suggesting that increased Fas cell surface expression is not due to increased protein synthesis alone. Neither IFN-g treatment nor Ad-IRF-1 infection altered IRF-2 expression ( Figure 3C ). Survivin levels consistently decreased following IFN-g treatment, but not following Ad-IRF-1 infection in Seg-1 cells, whereas the converse was true in Bic-1 and Flo-1 cells (Figure 3C ), suggesting that modulation of survivin is cell line-specific and that decreased survivin levels alone are not sufficient to induce apoptosis in Seg-1 cells. We concluded that the discrepancy between the ability of IFN-g and Ad-IRF-1 to induce apoptosis in these EA cells is not solely related to differential modulation of these apoptotic mediators.
IFN-g stimulation also activates pathways that antagonize apoptosis, including ERK2 [28] and c-Met [29, 30] , and we have previously shown universal overexpression of the hepatocyte growth factor receptor c-Met in EA [31] . We hypothesized that IFN-g treatment (but not Ad-IRF-1 infection) would activate ERK2 and c-Met signaling. Interestingly, both IFN-g and Ad-IRF-1 resulted in varying degrees of ERK2 phosphorylation ( Figure 3D ), but inhibition of ERK2 combined with IFN-g treatment did not induce apoptosis ( Figure 3E ). Likewise, inhibition of c-Met with PHA665752 did not sensitize these EA cells to IFN-g ( Figure 3E ). We concluded that IRF-1 at least partially modulates IFN-g -induced activation of ERK2, but that neither ERK2 nor c-Met signaling regulates IFN-g sensitivity in these EA cells. Taken together, these findings suggest that IRF-1 produced following IFN-g stimulation is functional and that activation of an undefined pathway may mediate IFN-g responsiveness in these EA cells.
In Vivo Administration of Ad-IRF-1 Decreases Tumor Growth Rates
Given our in vitro findings demonstrating that IRF-1 induces apoptosis in EA cells, we hypothesized that Ad-IRF-1 injection into established flank tumors in nude mice would result in tumor regression. Figure 4 demonstrates observed (dotted) and predicted (solid) growth rates of tumors measured every 3 to 4 days following treatment. There were no differences in mean tumor volumes on the first day of tumor measurements (day 10; P = .763) or on the final day of measurement (day 26; P = .618). A mixed quadratic model was fitted to log-transformed tumor volumes. A test for equality of slopes revealed modest evidence of interaction between treatment groups (PBS, Ad-C5, and Ad-IRF-1) and day of measurement (P = .062), suggesting unequal regression coefficients and differential tumor growth rates. The apparent difference in growth rate may be attributed to a decrease in growth rate for Ad-IRF-1 -treated mice. No negative effects of the treatment, such as local skin ulcers, reduction in activity, or decreased enteral intake, were observed in any of the mice. Tumors were resected at the conclusion of the experiment and analyzed for IRF-1 expression by immunostaining. IRF-1 immunoreactivity was not observed in either treatment group (data not shown). This was expected given the known rapid clearance of IRF-1 -transduced cells in vivo [27] . These results demonstrate that intratumoral delivery of Ad-IRF-1 modestly inhibits tumor growth rates in an in vivo model of EA, but does not lead to tumor regression.
Discussion
Our study is one of the few to investigate the role of IRF-1 in the pathophysiology and treatment of gastrointestinal malignancies and is the first to examine its role in EA. We have shown that IRF-1 overexpression induces apoptosis in EA cells in vitro and inhibits EA tumor growth rates in vivo. Little, if any, basal IRF-1 protein was detected in these EA cells, but all three cell lines expressed IRF-1 following IFN-g stimulation, suggesting that IRF-1 is not lost and that the IFN-g signaling pathway is functional. A supraphysiologic dose of IFN-g did not induce cell death, yet Ad-IRF-1 infection induced extensive apoptosis in all three cell lines. Additionally, in vivo administration of Ad-IRF-1 in a murine model of EA resulted in decreased rates of tumor growth relative to controls. Taken together, these findings support the use of strategies to augment IRF-1 expression as a therapeutic option for EA.
Studies in breast cancer have shown that IRF-1 expression is reduced or lost both in vitro and in vivo [32] . Similarly, we observed little, if any, IRF-1 expression in unstimulated EA cells. Ad-IRF-1 infection generates high levels of functional IRF-1 protein and induces apoptosis in breast cancer [19, 27] and other neoplasms [2] . Indeed, Ad-IRF-1 infection induced substantial apoptosis in vitro in two of the EA cell lines (Seg-1 and Flo-1), with lesser effects seen in Bic-1 cells. This finding may be attributable to reduced postinfection IRF-1 production in Bic-1 cells relative to Seg-1 and Flo-1 cells ( Figure 1B) . The possibility that Bic-1 cells are less sensitive to the effects of Ad-IRF-1, however, must be considered. Importantly, this Ad-IRF-1 induction of apoptosis is in contrast to our previous experience with other virally introduced proteins such as Adp53 that have not resulted in the induction of apoptosis [33] . Although IFN-g treatment alone induces apoptosis in some carcinoma models [12, 34] , resistance to IFN-g is common. Levels of IRF-1 may determine whether IFN-g induces apoptosis, and the amount of IRF-1 produced following IFN-g treatment may be regulated by the amount of IFN-g receptor (IFNGR) present [35, 36] or the rapid downregulation of IFNGR. Lack of IRF-1 expression in Seg-1 cells 48 hours following IFN-g stimulation ( Figure 1A) suggests that rapid downregulation of the IFNGR may occur in this cell line. Although it remains possible that Ad-IRF-1 infection generates more IRF-1 than IFN-g treatment, we did not observe a significant difference in the transduction of known targets of IRF-1 (i.e., Fas) between the two treatments.
IFN-g stimulation is also known to generate antagonistic effects simultaneous to those of IRF-1 (i.e., IRF-2), or to activate pathways that oppose IRF-1 function (i.e., c-Met and ERK2). IRF-2 is a putative oncogene and antagonizes IRF-1 by competing for the same DNA-binding sites [37] . All three of our EA cell lines abundantly express IRF-2 ( Figure 3C) ; although IRF-2 levels were not altered by IFN-g or Ad-IRF-1, overexpression of IRF-2 may inhibit responsiveness to IFN-g in these cell lines. c-Met and ERK activation typically results in cell proliferation and resistance to apoptosis [38, 39] , although our observations fail to support a significant role for c-Met or ERK in the regulation of IFN-g sensitivity. Collectively, our data suggest that other signaling events downstream of the IFNGR may counter IFN-g signaling through STAT-1.
Although inhibition of tumor growth rates following Ad-IRF-1 treatment in vivo did not reach statistical significance, a trend was apparent. Although repetition of in vivo experiments with more animals, larger doses of Ad-IRF-1, or smaller tumor burdens at the onset may have produced statistically significant results, we have not pursued this, as our current data suggest that replication-deficient adenoviral delivery through direct tumor injection will not produce an adequate clinical response to an established tumor [40] . Rather, we conclude that alternative viral delivery strategies need to be considered (i.e. retrovirus).
In summary, our study is the first to investigate the role of IRF-1 in the pathophysiology and treatment of EA. We have shown that IRF-1 overexpression induces the apoptosis of EA cells in vitro and modestly inhibits tumor growth rates in vivo. Taken together, our findings suggest that strategies designed to augment IRF-1 expression may be useful in the management of EA.
